Pacira BioSciences (PCRX) FCF Margin (2010 - 2026)

Pacira BioSciences' FCF Margin history runs 17 years deep, the most recent figure standing at 13.71% for Q1 2026.

• On a quarterly basis, FCF Margin fell 683.0% year-over-year to 13.71% in Q1 2026; TTM through Mar 2026 was 17.19%, a 701.0% decrease from a year earlier, with the FY2025 full-year figure at 18.81%, down 741.0% from the prior year.
• FCF Margin fell to 13.71% in Q1 2026 per PCRX's latest filing, from 22.08% in the prior quarter.
• Across five years, FCF Margin topped out at 31.73% in Q3 2025 and bottomed at 7.42% in Q4 2022.
• The 5-year median for FCF Margin is 20.54% (2025), against an average of 18.66%.
• Across the five-year window, FCF Margin plunged 3963 bps in 2022 and soared 2613 bps in 2023, its largest moves.
• Year by year, FCF Margin stood at 7.42% in 2022, then jumped by 352 bps to 18.7% in 2023, then increased by 3 bps to 19.27% in 2024, then grew by 15 bps to 22.08% in 2025, then tumbled by 38 bps to 13.71% in 2026.
• Per Business Quant, the three latest PCRX FCF Margin figures stand at 13.71% (Q1 2026), 22.08% (Q4 2025), and 31.73% (Q3 2025).